CENCORA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.9 USD | -0.75% |
|
-0.50% | +8.54% |
| 08/05 | Jefferies Adjusts Price Target on Cencora to $230 From $235 | MT |
| 03/05 | Wells Fargo Adjusts Cencora Price Target to $236 From $235 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 29TCr 24,24600Cr | Sales 2025 * | 31TCr 25,88000Cr | Capitalization | 4.45TCr 3,71100Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 201.1Cr 17TCr | Net income 2025 * | 232.7Cr 19TCr | EV / Sales 2024 * | 0.16 x |
| Net Debt 2024 * | 99Cr 8.25TCr | Net cash position 2025 * | 62Cr 5.21TCr | EV / Sales 2025 * | 0.14 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
18.6
x | Employees | 44,000 |
| Yield 2024 * |
0.92% | Yield 2025 * |
0.95% | Free-Float | 58.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cencora, Inc.
More recommendations
More press releases
More news
| 1 day | -0.75% | ||
| 1 week | -0.50% | ||
| Current month | -6.75% | ||
| 1 month | -4.74% | ||
| 3 months | -3.58% | ||
| 6 months | +12.09% | ||
| Current year | +8.54% |
1 week
222.58
228.25
1 month
222.20241.36
Current year
204.53246.75
1 year
163.37246.75
3 years
111.34246.75
5 years
72.06246.75
10 years
66.69246.75
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Collis
CEO | Chief Executive Officer | 62 | 01/94/01 |
James Cleary
DFI | Director of Finance/CFO | 61 | 01/15/01 |
Jennifer Dubas
CMP | Compliance Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kathleen Hyle
BRD | Director/Board Member | 65 | 13/10/13 |
| Director/Board Member | 74 | 25/08/25 | |
D. Mark Durcan
BRD | Director/Board Member | 62 | 08/15/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.85% | 2 M€ | +21.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 222.9 | -0.75% | 1,060,591 |
| 10/24/10 | 224.6 | +0.23% | 943,908 |
| 09/24/09 | 224.1 | -0.01% | 927,628 |
| 08/24/08 | 224.1 | -1.16% | 2,401,794 |
| 07/24/07 | 226.7 | +1.21% | 1,899,150 |
Delayed Quote Nyse, May 14, 2024 at 01:30 am IST
More quotes
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
Calendar
31/07/2024
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
222.9
USD
Average target price
254.5
USD
Spread / Average Target
+14.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.54% | 4.45TCr | |
| -4.82% | 18TCr | |
| +1.38% | 11TCr | |
| -2.82% | 6.85TCr | |
| +0.69% | 4.97TCr | |
| +2.33% | 4.07TCr | |
| +20.50% | 3.12TCr | |
| +1.72% | 2.61TCr | |
| +15.30% | 2.53TCr | |
| -1.73% | 2.46TCr |
- Stock Market
- Equities
- COR Stock